AdvaMed exodus continues
This article was originally published in The Gray Sheet
Associate VP-Payment & Policy Paul Seltman is the latest in a string of staff departures from the association, joining the Washington, D.C. office of law firm Gardner, Carton & Douglas the week of Sept. 27 as counsel on Capitol Hill and regulatory issues. At AdvaMed, Seltman is credited for recruiting member companies to the DIGHITS health information technology product sector. He also worked on Medicare inpatient payment issues for orthopedic firms. Exec VP-Technology & Regulatory Affairs Elizabeth Jacobson's last day at AdvaMed is Aug. 31, but she will be retained as a consultant through September...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.